État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle
Psychotropes April 23, 2018 Christian Sueur 3 citations
The therapeutic use of psychedelic substances began alongside the discovery of LSD and mescaline after World War II, initially for psychotherapy accompaniment, addiction treatment, and management of post-traumatic stress, resistant depression, obsessive and psychosomatic disorders, and end-of-life care. After medical use was banned in the 1960s, research halted except for a few experiments in the 1980s. Since 1994, clinical and neurobiological studies have resumed in most Western countries except France, focusing on addiction, psychotrauma, anxiety, depression, autism, and treatment-resistant schizophrenia, supported by foundations like MAPS and the Beckley Foundation.